CSL (STU:CSJ) ROCE %: 3.33% (As of Dec. 2025)


STU:CSJ CSL Ltd STU:CSJ
83 GF Score
Price €68.23
GF Value €165.40
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is CSL ROCE %?

CSL STU:CSJ -0.54% 83 ROCE % is 3.33% as of Dec. 2025. GuruFocus rates STU:CSJ with a GF Score™ of 83/100 and a GF Value™ of €165.40 (Significantly Undervalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CSL's annualized ROCE % for the quarter that ended in Dec. 2025 was 3.33%.

CSL  (STU:CSJ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CSL ROCE % Related Terms

CSL ROCE % Historical Data

* Premium members only.

The historical data trend for CSL's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL ROCE % Chart

CSL Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.39 16.97 11.50 11.77 11.76

CSL Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.69 16.18 7.30 0.00 3.33
STU:CSJ
83GF Score
CSL Ltd STU:CSJ
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSL ROCE % Calculation

CSL's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=3569.439/( ( (35322.438 - 4598.55) + (34163.268 - 4174.605) )/ 2 )
=3569.439/( (30723.888+29988.663)/ 2 )
=3569.439/30356.2755
=11.76 %

CSL's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=971.852/( ( (34163.268 - 4174.605) + (32368.308 - 3935.232) )/ 2 )
=971.852/( ( 29988.663 + 28433.076 )/ 2 )
=971.852/29210.8695
=3.33 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 3.33% mean?
CSL (STU:CSJ) has a ROCE % of 3.33% as of Dec. 2025.
Is CSL's ROCE % too high?
CSL's current ROCE % is 3.33%. Overall, CSL has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's ROCE % compare to VRTX and REGN?
CSL's ROCE % of 3.33% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. CSL's current ROCE % is 3.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (STU:CSJ) is currently considered Significantly Undervalued. The stock's GF Value™ is €165.40, compared to a current price of €68.23 — trading 58.7% below its estimated fair value. The current ROCE % is 3.33%. CSL's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For CSL (STU:CSJ), the current ROCE % is 3.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (STU:CSJ) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of €68.23 is trading 58.7% below its estimated GF Value™ of €165.40. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for STU:CSJ:

  • ROCE %: 3.33%
  • GF Value™: €165.40 vs. price of €68.23 (58.7% below fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the STU:CSJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
83GF Score

Get the complete analysis for STU:CSJ

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.23
Price
€165.40
GF Value